Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ophthalmology
Pharma
Apellis' weak quarter could signal Syfovre 'nadir': analysts
Apellis' geographic atrophy med Syfovre may have hit a performance “nadir” in 2024’s third quarter, one group of analysts contends.
Fraiser Kansteiner
Nov 5, 2024 3:41pm
EyePoint's Duravyu bounces back with promising DME data
Oct 28, 2024 1:11pm
Amgen gears up to launch Eylea biosim as Regeneron plots appeal
Oct 23, 2024 10:16am
Astellas cruises into first DTC campaign for GA med Izervay
Sep 30, 2024 4:00pm
EyePoint's Yutiq production lands in the FDA's crosshairs
Aug 27, 2024 4:07pm
AOA campaign riffs on tech product drops to promote eye health
Aug 26, 2024 10:47am
